Prospective Evaluation of PI-RADS Version 2.1 for Prostate Cancer Detection

The purpose of this study was to prospectively evaluate Prostate Imaging Reporting and Data and System version 2.1 (PI-RADSv2.1), which was released in March 2019 to update version 2.0, for prostate cancer detection with transrectal ultrasound-MRI fusion biopsy and 12-core systematic biopsy. This pr...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of roentgenology (1976) Vol. 215; no. 5; pp. 1098 - 1103
Main Authors Walker, Stephanie M., Mehralivand, Sherif, Harmon, Stephanie A., Sanford, Thomas, Merino, Maria J., Wood, Bradford J., Shih, Joanna H., Pinto, Peter A., Choyke, Peter L., Turkbey, Baris
Format Journal Article
LanguageEnglish
Published United States 01.11.2020
Subjects
multiparametric MRI
prostate biopsy
prostate cancer
early detection
PI-RADS
Online AccessGet full text

Cover

Abstract The purpose of this study was to prospectively evaluate Prostate Imaging Reporting and Data and System version 2.1 (PI-RADSv2.1), which was released in March 2019 to update version 2.0, for prostate cancer detection with transrectal ultrasound-MRI fusion biopsy and 12-core systematic biopsy. This prospective study included 110 consecutively registered patients who underwent multiparametric MRI evaluated with PI-RADSv2.1 criteria followed by fusion biopsy and systematic biopsy between April and September 2019. Lesion-based cancer detection rates (CDRs) were calculated for prostate cancer (Gleason grade group, > 0) and clinically significant prostate cancer (Gleason grade group, > 1). A total of 171 lesions (median size, 1.1 cm) in 110 patients were detected and evaluated with PI-RADSv2.1. In 16 patients no lesion was detected, and only systematic biopsy was performed. Lesions were categorized as follows: PI-RADS category 1, 1 lesion; PI-RADS category 2, 34 lesions; PI-RADS category 3, 54 lesions; PI-RADS category 4, 52 lesions; and PI-RADS category 5, 30 lesions. Histopathologic analysis revealed prostate cancer in 74 of 171 (43.3%) lesions and clinically significant prostate cancer in 57 of 171 (33.3%) lesions. The CDRs of prostate cancer for PI-RADS 2, 3, 4, and 5 lesions were 20.0%, 24.1%, 51.9%, and 90.0%. The CDRs of clinically significant prostate cancer for PI-RADS 1, 2, 3, 4, and 5 lesions were 0%, 5.7%, 14.8%, 44.2%, and 80.0%. In 16 patients with normal multiparametric MRI findings (PI-RADS 1), the CDRs were 50.0% for PCa and 18.8% for clinically significant prostate cancer. This investigation yielded CDRs assessed with prospectively assigned PI-RADSv2.1 scores. CDRs increased with higher PI-RADSv2.1 scores. These results can be compared with previously published outcomes derived with PI-RADS version 2.0.
AbstractList The purpose of this study was to prospectively evaluate Prostate Imaging Reporting and Data and System version 2.1 (PI-RADSv2.1), which was released in March 2019 to update version 2.0, for prostate cancer detection with transrectal ultrasound-MRI fusion biopsy and 12-core systematic biopsy. This prospective study included 110 consecutively registered patients who underwent multiparametric MRI evaluated with PI-RADSv2.1 criteria followed by fusion biopsy and systematic biopsy between April and September 2019. Lesion-based cancer detection rates (CDRs) were calculated for prostate cancer (Gleason grade group, > 0) and clinically significant prostate cancer (Gleason grade group, > 1). A total of 171 lesions (median size, 1.1 cm) in 110 patients were detected and evaluated with PI-RADSv2.1. In 16 patients no lesion was detected, and only systematic biopsy was performed. Lesions were categorized as follows: PI-RADS category 1, 1 lesion; PI-RADS category 2, 34 lesions; PI-RADS category 3, 54 lesions; PI-RADS category 4, 52 lesions; and PI-RADS category 5, 30 lesions. Histopathologic analysis revealed prostate cancer in 74 of 171 (43.3%) lesions and clinically significant prostate cancer in 57 of 171 (33.3%) lesions. The CDRs of prostate cancer for PI-RADS 2, 3, 4, and 5 lesions were 20.0%, 24.1%, 51.9%, and 90.0%. The CDRs of clinically significant prostate cancer for PI-RADS 1, 2, 3, 4, and 5 lesions were 0%, 5.7%, 14.8%, 44.2%, and 80.0%. In 16 patients with normal multiparametric MRI findings (PI-RADS 1), the CDRs were 50.0% for PCa and 18.8% for clinically significant prostate cancer. This investigation yielded CDRs assessed with prospectively assigned PI-RADSv2.1 scores. CDRs increased with higher PI-RADSv2.1 scores. These results can be compared with previously published outcomes derived with PI-RADS version 2.0.
OBJECTIVE. The purpose of this study was to prospectively evaluate Prostate Imaging Reporting and Data and System version 2.1 (PI-RADSv2.1), which was released in March 2019 to update version 2.0, for prostate cancer detection with transrectal ultrasound-MRI fusion biopsy and 12-core systematic biopsy. SUBJECTS AND METHODS. This prospective study included 110 consecutively registered patients who underwent multiparametric MRI evaluated with PI-RADSv2.1 criteria followed by fusion biopsy and systematic biopsy between April and September 2019. Lesion-based cancer detection rates (CDRs) were calculated for prostate cancer (Gleason grade group, > 0) and clinically significant prostate cancer (Gleason grade group, > 1). RESULTS. A total of 171 lesions (median size, 1.1 cm) in 110 patients were detected and evaluated with PI-RADSv2.1. In 16 patients no lesion was detected, and only systematic biopsy was performed. Lesions were categorized as follows: PI-RADS category 1, 1 lesion; PI-RADS category 2, 34 lesions; PI-RADS category 3, 54 lesions; PI-RADS category 4, 52 lesions; and PI-RADS category 5, 30 lesions. Histopathologic analysis revealed prostate cancer in 74 of 171 (43.3%) lesions and clinically significant prostate cancer in 57 of 171 (33.3%) lesions. The CDRs of prostate cancer for PI-RADS 2, 3, 4, and 5 lesions were 20.0%, 24.1%, 51.9%, and 90.0%. The CDRs of clinically significant prostate cancer for PI-RADS 1, 2, 3, 4, and 5 lesions were 0%, 5.7%, 14.8%, 44.2%, and 80.0%. In 16 patients with normal multiparametric MRI findings (PI-RADS 1), the CDRs were 50.0% for PCa and 18.8% for clinically significant prostate cancer. CONCLUSION. This investigation yielded CDRs assessed with prospectively assigned PI-RADSv2.1 scores. CDRs increased with higher PI-RADSv2.1 scores. These results can be compared with previously published outcomes derived with PI-RADS version 2.0.OBJECTIVE. The purpose of this study was to prospectively evaluate Prostate Imaging Reporting and Data and System version 2.1 (PI-RADSv2.1), which was released in March 2019 to update version 2.0, for prostate cancer detection with transrectal ultrasound-MRI fusion biopsy and 12-core systematic biopsy. SUBJECTS AND METHODS. This prospective study included 110 consecutively registered patients who underwent multiparametric MRI evaluated with PI-RADSv2.1 criteria followed by fusion biopsy and systematic biopsy between April and September 2019. Lesion-based cancer detection rates (CDRs) were calculated for prostate cancer (Gleason grade group, > 0) and clinically significant prostate cancer (Gleason grade group, > 1). RESULTS. A total of 171 lesions (median size, 1.1 cm) in 110 patients were detected and evaluated with PI-RADSv2.1. In 16 patients no lesion was detected, and only systematic biopsy was performed. Lesions were categorized as follows: PI-RADS category 1, 1 lesion; PI-RADS category 2, 34 lesions; PI-RADS category 3, 54 lesions; PI-RADS category 4, 52 lesions; and PI-RADS category 5, 30 lesions. Histopathologic analysis revealed prostate cancer in 74 of 171 (43.3%) lesions and clinically significant prostate cancer in 57 of 171 (33.3%) lesions. The CDRs of prostate cancer for PI-RADS 2, 3, 4, and 5 lesions were 20.0%, 24.1%, 51.9%, and 90.0%. The CDRs of clinically significant prostate cancer for PI-RADS 1, 2, 3, 4, and 5 lesions were 0%, 5.7%, 14.8%, 44.2%, and 80.0%. In 16 patients with normal multiparametric MRI findings (PI-RADS 1), the CDRs were 50.0% for PCa and 18.8% for clinically significant prostate cancer. CONCLUSION. This investigation yielded CDRs assessed with prospectively assigned PI-RADSv2.1 scores. CDRs increased with higher PI-RADSv2.1 scores. These results can be compared with previously published outcomes derived with PI-RADS version 2.0.
Author Shih, Joanna H.
Mehralivand, Sherif
Pinto, Peter A.
Merino, Maria J.
Wood, Bradford J.
Harmon, Stephanie A.
Walker, Stephanie M.
Sanford, Thomas
Choyke, Peter L.
Turkbey, Baris
AuthorAffiliation 1 Molecular Imaging Program, National Cancer Institute, National Institutes of Health, 10 Center Dr, Rm B3B85, Bethesda, MD 20892
6 Biometric Research Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
5 Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD
4 Center for Interventional Oncology, National Cancer Institute, Bethesda, MD
2 Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Bethesda, MD
7 Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
3 Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD
AuthorAffiliation_xml – name: 5 Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD
– name: 7 Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
– name: 3 Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD
– name: 1 Molecular Imaging Program, National Cancer Institute, National Institutes of Health, 10 Center Dr, Rm B3B85, Bethesda, MD 20892
– name: 2 Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Bethesda, MD
– name: 6 Biometric Research Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
– name: 4 Center for Interventional Oncology, National Cancer Institute, Bethesda, MD
Author_xml – sequence: 1
  givenname: Stephanie M.
  surname: Walker
  fullname: Walker, Stephanie M.
  organization: Molecular Imaging Program, National Cancer Institute, National Institutes of Health, 10 Center Dr, Rm B3B85, Bethesda, MD 20892
– sequence: 2
  givenname: Sherif
  surname: Mehralivand
  fullname: Mehralivand, Sherif
  organization: Molecular Imaging Program, National Cancer Institute, National Institutes of Health, 10 Center Dr, Rm B3B85, Bethesda, MD 20892
– sequence: 3
  givenname: Stephanie A.
  surname: Harmon
  fullname: Harmon, Stephanie A.
  organization: Molecular Imaging Program, National Cancer Institute, National Institutes of Health, 10 Center Dr, Rm B3B85, Bethesda, MD 20892., Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Bethesda, MD
– sequence: 4
  givenname: Thomas
  surname: Sanford
  fullname: Sanford, Thomas
  organization: Molecular Imaging Program, National Cancer Institute, National Institutes of Health, 10 Center Dr, Rm B3B85, Bethesda, MD 20892
– sequence: 5
  givenname: Maria J.
  surname: Merino
  fullname: Merino, Maria J.
  organization: Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD
– sequence: 6
  givenname: Bradford J.
  surname: Wood
  fullname: Wood, Bradford J.
  organization: Center for Interventional Oncology, National Cancer Institute, Bethesda, MD., Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD
– sequence: 7
  givenname: Joanna H.
  surname: Shih
  fullname: Shih, Joanna H.
  organization: Biometric Research Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
– sequence: 8
  givenname: Peter A.
  surname: Pinto
  fullname: Pinto, Peter A.
  organization: Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
– sequence: 9
  givenname: Peter L.
  surname: Choyke
  fullname: Choyke, Peter L.
  organization: Molecular Imaging Program, National Cancer Institute, National Institutes of Health, 10 Center Dr, Rm B3B85, Bethesda, MD 20892
– sequence: 10
  givenname: Baris
  surname: Turkbey
  fullname: Turkbey, Baris
  organization: Molecular Imaging Program, National Cancer Institute, National Institutes of Health, 10 Center Dr, Rm B3B85, Bethesda, MD 20892
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32877244$$D View this record in MEDLINE/PubMed
BookMark eNptkUlPwzAQhS1UBG3hxhnlyIEU74kvSFVb1kpUZRE3y0kcCErjYruV-Pc4FBAgTrbG35sZv9cDncY0GoADBAcYI3oyvJoPkAh3nogt0EWM8pggijqgCwlHcQrJ4y7oOfcCIUxSkeyAXYLTJMGUdsH1zBq31Lmv1jqarFW9Ur4yTWTKaHYZz4fj2-hBW9eW8ABFpbFRq_DK62ikmlzbaKx9qzfNHtguVe30_ufZB_dnk7vRRTy9Ob8cDadxThn0cZGJgnGFC54WBSM0LF6WtMxophjjrBCM45TmhGSKihImLNVZIYjmocSVSEgfnG76LlfZQhe5brxVtVzaaqHsmzSqkr9fmupZPpm1DJ-nIqWhwdFnA2teV9p5uahcrutaNdqsnMSUCJFwzHFAD3_O-h7y5WAAjjdAHmxxVpffCIKyDUiGgCQS8iOggOM_eF75D8vDplX9v-gd_8iSuQ
CitedBy_id crossref_primary_10_1038_s41598_024_56415_5
crossref_primary_10_2214_AJR_20_24493
crossref_primary_10_1002_jmri_27546
crossref_primary_10_1097_CCO_0000000000000717
crossref_primary_10_1186_s43055_024_01244_9
crossref_primary_10_1038_s41391_021_00417_1
crossref_primary_10_1093_jncics_pkae014
crossref_primary_10_1093_postmj_qgad127
crossref_primary_10_1148_radiol_221798
crossref_primary_10_1148_radiol_221309
crossref_primary_10_1016_j_prro_2024_06_006
crossref_primary_10_1038_s41391_022_00599_2
crossref_primary_10_1111_ijcp_14654
crossref_primary_10_1259_bjr_20210509
crossref_primary_10_2214_AJR_23_30611
crossref_primary_10_3233_CH_209225
crossref_primary_10_1007_s00330_024_10734_3
crossref_primary_10_1148_radiol_233337
crossref_primary_10_1007_s00261_024_04506_2
crossref_primary_10_1038_s41598_023_44215_2
crossref_primary_10_1007_s11604_024_01675_4
Cites_doi 10.1016/j.juro.2017.03.131
10.1001/jama.2014.17942
10.1056/NEJMc1807507
10.1007/s00330-011-2377-y
10.1016/j.eururo.2015.08.052
10.2214/AJR.13.11046
10.1111/biom.12653
10.1002/jmri.25948
10.3322/caac.21551
10.1016/S0140-6736(16)32401-1
10.1002/jmri.26555
10.1016/j.eururo.2015.06.046
10.1016/S0022-5347(05)66086-7
ContentType Journal Article
DBID AAYXX
CITATION
NPM
7X8
5PM
DOI 10.2214/AJR.19.22679
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1546-3141
EndPage 1103
ExternalDocumentID PMC8974984
32877244
10_2214_AJR_19_22679
Genre Journal Article
GrantInformation_xml – fundername: Intramural NIH HHS
  grantid: Z01 BC011081
– fundername: Intramural NIH HHS
  grantid: Z01 SC000853
– fundername: Intramural NIH HHS
  grantid: ZID BC011242
– fundername: CCR NIH HHS
  grantid: HHSN261200800001C
– fundername: Intramural NIH HHS
  grantid: Z01 BC010655
– fundername: NCI NIH HHS
  grantid: HHSN261200800001E
GroupedDBID ---
-DD
.55
.GJ
1CY
1KJ
23M
2WC
34G
39C
3O-
53G
5GY
5RE
AAEJM
AAWTL
AAYXX
ABOCM
ADBBV
AENEX
AFFNX
AI.
AJJEV
ALMA_UNASSIGNED_HOLDINGS
BAWUL
C1A
CITATION
CS3
DIK
E3Z
EBS
EJD
F5P
GX1
H13
J5H
L7B
LSO
MJL
P2P
SJN
TR2
TRR
TWZ
UDS
VH1
W2D
W8F
WH7
WOQ
X7M
YJK
YQI
YQJ
ZGI
ZVN
ZXP
NPM
7X8
5PM
ID FETCH-LOGICAL-c450t-db9d56a2d68dd534267ff4fb4ba5565d956284c33ba49f0758ebd93e6c336a973
ISSN 0361-803X
1546-3141
IngestDate Thu Aug 21 18:16:51 EDT 2025
Fri Jul 11 06:37:47 EDT 2025
Sat May 31 02:11:11 EDT 2025
Thu Apr 24 23:05:03 EDT 2025
Tue Jul 01 01:22:37 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords multiparametric MRI
prostate biopsy
prostate cancer
early detection
PI-RADS
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c450t-db9d56a2d68dd534267ff4fb4ba5565d956284c33ba49f0758ebd93e6c336a973
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/8974984
PMID 32877244
PQID 2439976262
PQPubID 23479
PageCount 6
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_8974984
proquest_miscellaneous_2439976262
pubmed_primary_32877244
crossref_primary_10_2214_AJR_19_22679
crossref_citationtrail_10_2214_AJR_19_22679
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-11-01
PublicationDateYYYYMMDD 2020-11-01
PublicationDate_xml – month: 11
  year: 2020
  text: 2020-11-01
  day: 01
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle American journal of roentgenology (1976)
PublicationTitleAlternate AJR Am J Roentgenol
PublicationYear 2020
References R2
R3
R4
R5
R6
R7
R8
R9
R10
R12
R11
R14
R1
33464932 - J Urol. 2021 Apr;205(4):1205-1206. doi: 10.1097/JU.0000000000001619.
References_xml – ident: R12
  doi: 10.1016/j.juro.2017.03.131
– ident: R11
  doi: 10.1001/jama.2014.17942
– ident: R10
  doi: 10.1056/NEJMc1807507
– ident: R5
  doi: 10.1007/s00330-011-2377-y
– ident: R6
  doi: 10.1016/j.eururo.2015.08.052
– ident: R3
  doi: 10.2214/AJR.13.11046
– ident: R9
  doi: 10.1111/biom.12653
– ident: R14
  doi: 10.1002/jmri.25948
– ident: R1
  doi: 10.3322/caac.21551
– ident: R4
  doi: 10.1016/S0140-6736(16)32401-1
– ident: R7
  doi: 10.1002/jmri.26555
– ident: R8
  doi: 10.1016/j.eururo.2015.06.046
– ident: R2
  doi: 10.1016/S0022-5347(05)66086-7
– reference: 33464932 - J Urol. 2021 Apr;205(4):1205-1206. doi: 10.1097/JU.0000000000001619.
SSID ssj0007897
Score 2.4728117
Snippet The purpose of this study was to prospectively evaluate Prostate Imaging Reporting and Data and System version 2.1 (PI-RADSv2.1), which was released in March...
OBJECTIVE. The purpose of this study was to prospectively evaluate Prostate Imaging Reporting and Data and System version 2.1 (PI-RADSv2.1), which was released...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1098
Title Prospective Evaluation of PI-RADS Version 2.1 for Prostate Cancer Detection
URI https://www.ncbi.nlm.nih.gov/pubmed/32877244
https://www.proquest.com/docview/2439976262
https://pubmed.ncbi.nlm.nih.gov/PMC8974984
Volume 215
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSFUviDfLS0aCU5Rl4ziJfaxKoRQtQn2IvUV2YquV2qQKKQd-PeNXkl2oBFyiPB3J36fJzGTmM0JvZJUwXvAqFgw2lNca9giLxUKrii0EzawS0_JLfnBKD1fZaszp2u6SXs6rn3_sK_kfVOEc4Gq6ZP8B2WFQOAH7gC9sAWHY_hXGX7s2dEpG-4Nsty1r-xQf7b4_jnw6LCLzxBYUmieMexntGbQ7MDe9rcVqpk7q8BdnIivRtfB1MoKuVrLJqDuBhzFJI3wTF74-w9aNmcb1MdG6VGcmn_LDF1EaOchzPdq-7tL9-h-fHGh1LJpQfT8pZfJZCghJkyFLobxlpTkYfKdyFUwvca2cnmPZxJAmC7c49aaFJyShRmni8GiecDjK3VI0E7CvLi3aKYSCBXHakhuK2uHSbXSHwI5Z9-LjaiwMKoC8rkXCvOzd9FU7aDs8vO7H_BacbNbYTpyWk3voro828K6jzn10SzUP0PbS11M8RJ8nDMIjg3CrsWcQ9gzCwCAMUODAIOwYhAcGPUKnH_ZP9g5iv7xGXNFs0ce15HWWC1LnrK6zFFy1QmuqJZUiAze_hsgZfJcqTaWgXINryZSseapyOJULXqSP0VbTNuopwgKCfvCsdcEy-CgQs2qhFoKzXChZpFU6Q1GYrLLy2vNmCZSLEmJQM8slzHKZ8NLO8gy9He6-cporN9z3Osx7CUbR_OkSjWqvv5fERNnwmc_JDD1xOAwjBQBnqFhDaLjBCK6vX2nOz6zwOhCDckaf3Tjmc7Qzkv8F2uq7a_USnNZevrIc-wXu9JVV
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prospective+Evaluation+of+PI-RADS+Version+2.1+for+Prostate+Cancer+Detection&rft.jtitle=American+journal+of+roentgenology+%281976%29&rft.au=Walker%2C+Stephanie+M&rft.au=Mehralivand%2C+Sherif&rft.au=Harmon%2C+Stephanie+A&rft.au=Sanford%2C+Thomas&rft.date=2020-11-01&rft.eissn=1546-3141&rft.volume=215&rft.issue=5&rft.spage=1098&rft_id=info:doi/10.2214%2FAJR.19.22679&rft_id=info%3Apmid%2F32877244&rft.externalDocID=32877244
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0361-803X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0361-803X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0361-803X&client=summon